A guide to applying USP 800 guidelines after the NIOSH update

The 2024 NIOSH List of Hazardous Drugs introduces important changes that may affect how healthcare organizations classify, assess, and manage hazardous drugs. Its revised two-table structure emphasizes occupational hazard characteristics rather than grouping drugs primarily by therapeutic use. 

This guide provides a practical roadmap to help pharmacy and healthcare leaders respond to these changes by:

  • Understanding the updated NIOSH classification tables and their implications
  • Determining when full USP <800> containment or an Assessment of Risk may apply
  • Reviewing hazardous drug lists, policies, procedures, and formulary processes
  • Reassessing workflows across receiving, storage, preparation, administration, transport, cleaning, and disposal
  • Updating staff training and competency programs across affected departments
  • Building a sustainable, organization-wide approach to hazardous drug safety

Whether your organization is refining an established program or responding to the updated NIOSH List, this guide can help translate current guidance into practical, sustainable action. 

Please fill out the form to access the guide

Key Findings

What changed in the 2024 NIOSH List of Hazardous Drugs?

The 2024 NIOSH List shifts from three tables to two, placing greater emphasis on the occupational hazards associated with each drug rather than primarily grouping drugs by therapeutic use. The revised structure affects how healthcare facilities evaluate hazardous drugs, determine containment requirements, and document Assessments of Risk.

Key considerations include:

Table 1 changes
Table 1 includes certain CDER-approved medications with manufacturer special handling information and/or drugs meeting specified carcinogenicity criteria. Fifteen medications transitioned from the former Table 2 into Table 1.

Table 2 consolidation
Table 2 consolidates the former Tables 2 and 3 and includes CDER-approved, non-nuclear, non-MSHI medications associated with reproductive, genotoxic, or organ toxicity risks, but are not explicitly indexed as known or probable human carcinogens by NTP or IARC.

Biologics and newer drugs
Facilities must independently evaluate certain biologics and drugs approved after the list’s data cutoff to determine appropriate handling and containment strategies.

Assessment of risk implications
USP <800> “antineoplastic” requirements apply only to agents in Table 1 of the current NIOSH List. As a result, some drugs previously requiring full containment may now qualify for an Assessment of Risk, while newly classified hazardous drugs may require full containment. The guide includes a decision pathway to help determine which approach applies.

Putting USP 800 guidelines into practice

1. Build the administrative and policy framework

Identify the designated person responsible for continuous oversight of hazardous drug handling and compliance. Update SOPs to reflect revised terminology, classifications, workflows, containment strategies, and processes for evaluating new formulary additions.

2. Manage the HD lifecycle

Evaluate each point where occupational exposure could occur, including receipt, storage, preparation, dispensing, transport, administration, waste handling, spill response, cleaning, and disposal. Include departments and personnel beyond the pharmacy.

3. Standardize training

Provide role-specific education before personnel handle newly listed or reclassified drugs or implement revised procedures. Establish a process for communicating future NIOSH updates and internal hazardous drug reassessments.

4. Review resources

Clinicians should also consult NIOSH, USP and ASHP’s hazardous drug resources to develop a foundation for understanding an effective hazardous drug program. As regulators may have different expectations, facilities should also review guidance from applicable federal and state enforcement agencies, including state boards of pharmacy, for any additional or state-specific expectations.

Actionable Insights

Discover more Simplifi+ Pharmacy Compliance resources

Simplifi+ provides resources to help healthcare organizations build and sustain pharmacy compliance programs. The platform includes customizable policies and procedures, competency and training tools, guided workflow support, and continuing education content.
Access the Guide
Explore Simplifi 797
Back To Top